Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIRECT Trial
NCT05710328Phase 2Active, not recruiting
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Start
- May 2023
- Primary completion
- May 2027
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of fludeoxyglucose f 18 in breast cancer, sponsored by ECOG-ACRIN Cancer Research Group. Primary endpoint: Negative predictive value of neoadjuvant interim FDG-PET/CT for pathologic complete response at 5 years. Started May 2023; status: active, not recruiting.
02
Drugs
fludeoxyglucose f 18
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05710328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05710328.